Page 43 of GILD slide deck shows GILD at 61% of US HCV market - up 19% from Jan 19. Also interesting is that patient starts have stayed very high (JMO). Since US HCV revenue flat YOY when starts are up >30%, it must be from lower pricing (generic).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.